Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

Provided By GlobeNewswire – Last update:

Quotes Stocks Mentioned

Article Mentions:

DSGN (12.04 ▼ -3.60%)

Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing

Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) Program

Read more at globenewswire.com